AzentaAZTA
AZTA
About: Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.
Employees: 3,300
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1.07% less ownership
Funds ownership: 103.07% [Q2] → 102.0% (-1.07%) [Q3]
3% less funds holding
Funds holding: 317 [Q2] → 306 (-11) [Q3]
14% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 51
17% less capital invested
Capital invested by funds: $2.92B [Q2] → $2.42B (-$507M) [Q3]
32% less repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 130
50% less funds holding in top 10
Funds holding in top 10: 2 [Q2] → 1 (-1) [Q3]
53% less call options, than puts
Call options by funds: $9.45M | Put options by funds: $20.2M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$55
5%
upside
Avg. target
$58
9%
upside
High target
$60
14%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Stephens & Co. Jacob Johnson 58% 1-year accuracy 11 / 19 met price target | 14%upside $60 | Overweight Reiterated | 2 Jan 2025 |
Needham David Saxon 34% 1-year accuracy 21 / 62 met price target | 5%upside $55 | Buy Maintained | 13 Nov 2024 |
Financial journalist opinion
Positive
Zacks Investment Research
1 month ago
Azenta (AZTA) Surges 7.2%: Is This an Indication of Further Gains?
Azenta (AZTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Neutral
CNBC Television
1 month ago
Final Trade: BABA, GOOGL, AZTA, GDX
The final trades of the day with the Fast Money traders.
Neutral
PRNewsWire
2 months ago
Flex Set to Join S&P MidCap 400; Azenta and Concentra Group Holdings to Join S&P SmallCap 600
NEW YORK , Nov. 19, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Flex Ltd (NASD: FLEX) will replace Azenta Inc. (NASD: AZTA) in the S&P MidCap 400, and Azenta will replace Envestnet Inc. (NYSE: ENV) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, November 25. Bain Capital is acquiring Envestnet in a deal expected to be completed soon, pending final closing conditions.
Neutral
PRNewsWire
2 months ago
Azenta to Participate in Stephens Annual Investment Conference
BURLINGTON, Mass. , Nov. 14, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in Stephens Annual Investment Conference, on Wednesday November 20, 2024, which includes a presentation beginning at 1:00 pm CT.
Neutral
Seeking Alpha
2 months ago
Azenta, Inc. (AZTA) Q4 2024 Earnings Call Transcript
Azenta, Inc. (NASDAQ:AZTA ) Q4 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Yvonne Perron - Vice President, FP&A and Investor Relations John Marotta - President and Chief Executive Officer Herman Cueto - Executive Vice President and Chief Financial Officer Conference Call Participants David Saxon - Needham & Company Vijay Kumar - Evercore ISI Jacob Johnson - Stephens Andrew Cooper - Raymond James Matt Stanton - Jefferies Lucas Baranowski - KeyBanc Capital Operator Greetings and welcome to the Azenta Fourth Quarter 2024 Financial Results. During the presentation, all lines will be in a listen-only mode.
Positive
Zacks Investment Research
2 months ago
Azenta (AZTA) Q4 Earnings Top Estimates
Azenta (AZTA) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.13 per share a year ago.
Neutral
PRNewsWire
2 months ago
Azenta Reports Fourth Quarter and Full Year Fiscal 2024 Results; Announces the Plan to Sell B Medical Systems and Appoints Lawrence Y. Lin as CFO
FY'24 revenue growth of 4%, reported and organic, in combined Sample Management Solutions and Multiomics FY'25 organic revenue growth expected to be 3% to 5% year over year, with Adjusted EBITDA margin expansion of approximately 300 basis points Pursuing a sale of B Medical Systems to simplify portfolio and drive revenue growth and profitability Announces appointment of Lawrence Y. Lin as Chief Financial Officer; Herman Cueto to remain as advisor to ensure smooth transition BURLINGTON, Mass.
Neutral
PRNewsWire
2 months ago
Azenta Announces Fiscal 2024 Fourth Quarter and Full Year Earnings Conference Call and Webcast
BURLINGTON, Mass. , Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal fourth quarter and full year 2024 earnings which ended on September 30, 2024, on Tuesday, November 12, 2024, after the market closes.
Neutral
PRNewsWire
2 months ago
Azenta Announces the Addition of Three New Independent Directors Effective Immediately and New Initiative to Drive Value
William L. Cornog, Quentin Koffey and Alan J. Malus Add Deep Industry Expertise and Track Records of Shareholder Value Creation to the Board Establishes Value Creation Committee of the Board Comprised of New Directors, CEO John Marotta, and Current Director Martin Madaus Reaffirms Full-Year 2024 Financial Guidance BURLINGTON, Mass.
Neutral
PRNewsWire
2 months ago
Azenta Obtains Regulatory Approval for Clinical Long-Read Whole Genome Sequencing Test
BURLINGTON, Mass. , Oct. 30, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the launch of a long-read Whole Genome Sequencing (WGS) test for clinical applications.
Charts implemented using Lightweight Charts™